Peptidome data-driven comprehensive individualized monitoring of membranous nephropathy with machine learning

As the most common pathological type of nephrotic syndrome,membranous nephropathy(MN)presents diversity in progression trends,facing severe complications.The precise discrimination of MN from healthy people,other types of nephrotic syndrome or those with therapeutic remission has always been huge challenge in clinics,not to mention comprehensive individualized monitoring relied on minimally invasive molecular detection means.Herein,we construct a functionalized pore architecture to couple with machine learning to aid all-round peptidome enrichment and data profiling from hundreds of human serum samples,and finally establish a set of defined peptide panel consisting of 12 specific feature signals.In addition to the realization of above-mentioned precise discrimination with more than 97%of sensitivity,88%of accuracy and f1 score,the simultaneously comprehensive individualized monitoring for MN can also be achieved,including conventionally screening diagnosis,congeneric distinction and prognostic evaluation.This work greatly advances the development of peptidome data-driven individualized monitoring means for complex diseases and undoubtedly inspire more devotion into molecular detection field.

Chinese expert consensus on the clinical application of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease

The prevalence of chronic kidney disease(CKD)in China was 8.2%in 2018-2019.[1]CKD may progress to end-stage kidney disease(ESKD),necessitating kidney replacement treatment such as dialysis or kidney transplantation,[2]which imposes a substantial burden on both family and society.Moreover,patients with CKD have a high risk of comorbidities including cardiovascular diseases.[3]The risk of death rises as the estimated glomerularltration rate(eGFR)declines.[3]A substantial portion of CKD patients die,primarily from cardiovascular events,before reaching the stage requiring dialysis.[3]As such,delaying the progression of CKD and reducing cardiovascular events are key elements in patient care.In recent years,important progress has been made in the cardiorenal protection of patients with CKD.Specically,the advent of sodium-glucose cotransporter 2(SGLT2)inhibitors has provided a new and important approach for the treatment of CKD.